Journal
HEART LUNG AND CIRCULATION
Volume 22, Issue 2, Pages 100-103Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hlc.2012.08.055
Keywords
Acute massive pulmonary embolism; Postoperative thrombolysis
Categories
Funding
- Changjiang Scholars and Innovative Research Team in University grant [IRT0961]
- Guangdong Natural Science Foundation team [1035101200300000]
- Guangzhou Department of Education Yangcheng Scholarship [10A058S]
Ask authors/readers for more resources
Purpose: The standard medical management for patients with acute massive pulmonary embolism (MPE) is systemic thrombolysis. However, it is generally thought that recent surgeries are a contraindication to thrombolytic therapy. In this study, we evaluated the efficacy and safety of systemic thrombolysis for postoperative patients with acute MPE and assessed the risk of bleeding. Methods: A retrospective review was performed on 21 postoperative patients with MPE in a timeframe of five years (from 2005 to 2010). The criteria for study inclusion were postoperative patients who received systemic thrombolysis for confirmed acute MPE within three weeks after surgery. Results: Seventeen postoperative patients, including men (12) and women (five) aged 53 +/- 16 (range 23-71) years, were treated with systemic thrombolysis. Significant haemodynamic improvement (shock index < 0.9) was observed in 16 of 17 cases (94%). The remaining patient (6%) died of cardiac arrest within 24 h. No major bleeding complication was observed. Sixteen patients survived and remained stable for 34 +/- 16 (range 11-52) days until hospital discharge. Conclusion: Recent surgery is not an absolute contraindication to systemic thrombolysis. Further, to obtain a successful outcome, it is crucial to exclude patients who have received neurosurgical operations or those with other contraindications to thrombolytic therapy. (Heart, Lung and Circulation 2013;22:100-103) (C) 2012 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available